Get these analyses to your inbox — https://axialobservations.substack.com/ This is a newsletter for rough-around-the-edges ideas. More well thought out work can be found at — https://axial.substack.com/ I figured that there is a diversity across desire for frequency of emails.
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
A set of ideas and observations from a week’s worth of work analyzing businesses and technologies.
Live-attenuated and inactivated vaccines
Live-attenuated and inactivated (LAI) vaccines are an old technology that will probably solve the new problem of COVID-19. I’m just not sure what the timeline is — 18 months or 5 years? This is where new modalities have an advantage acceleration to the clinic. It’s the difference between a 718 and a Cayenne. I’m pretty excited to see how the AAV-based vaccines work against COVID-19. However, the best shot for a successful vaccine is probably a live-attenuated or inactivated vaccine.
The process to invent a successful LAI vaccine has to focus on safety because you’re putting the virus itself into a patient and is a trial-and-error process to figure out which components are essential to activate a good immune response while not potentially killing the patient. Whereas, an mRNA vaccine just involves printing RNA…
